慢性肾小球肾炎（CGN）患者肾组织病理生成和进行性损伤中涉及多种细胞因子和化学因子。本研究的目的是确定新诊断的CGN患者尿液中白细胞介素6（IL-6）、转化生长因子β1（TGFβ1）、单核细胞趋化因子（MCP-1）、可溶性肿瘤坏死因子受体1（sTNFR1）和表皮生长因子（EGF）的排泄能否作为预后生物标志物，并且能否在前瞻观察中有效预测肾功能的进行性减退。该研究包括150名高加索人患者。使用ELISA方法（Quantikine R&D System）测量尿液中的IL-6、TGFβ1、MCP-1、sTNFR1和EGF。在肾病患者、出现时估计的肾小球滤过率（eGFR）< 60/min/1.73m2的患者以及进展者（PG）亚组中，UIL-6、UTGFβ1、UMCP-1和UsTNFR1显著增加，而UEGF排泄明显降低。在多元回归分析中，基础eGFR与UsTNFR1、UIL-6和UEGF排泄呈相关性，然而在随访过程中，ΔeGFR（估计的肾小球滤过率变化）仅与UEGF排泄显著相关。逻辑回归分析显示，时间内肾功能恶化最显著的独立风险因素是最初较高（> 11.8 pg/mgCr）的UIL-6排泄、最初较低（< 15.5 ng/mgCr）的尿液UEGF排泄和男性。在新诊断的CGN患者中，UIL-6和UEGF可作为疾病进展的预后生物标志物。

Several cytokines and chemokines are involved in the pathogenesis and progressive injury of renal tissues in patients with primary chronic glomerulonephritis (CGN). The objective of this study was to determine whether the urinary excretion of interleukin-6 (IL-6), transforming growth factor β1 (TGFβ1), monocytes chemoattractant protein (MCP-1), soluble tumor necrosis factor receptor 1 (sTNFR1) and epidermal growth factor (EGF) in patients with newly recognized CGN can serve as prognostic biomarkers in patients with newly recognized CGN and whether they can be effective in predicting a progressive reduction of renal function in prospective observation. The study included 150 Caucasian patients. UIL-6, UTGFβ1, UMCP-1 and UsTNFR1 and UEGF were measured using ELISA methods (Quantikine R&D System). UIL-6, UTGFβ1, UMCP-1 and UsTNFR1 were significantly higher, yet UEGF excretion was significantly lower in nephrotic patients, in patients with estimated glomerular filtration rate (eGFR) < 60/min/1,73m2 at presentation, as well as in the progressor (PG) subgroup. In a multivariate regression analysis basal eGFR correlated with UsTNFR1, UIL-6 and UEGF excretion, although in the follow-up, ΔeGFR (delta estimated glomerular filtration rate) significantly correlated only with UEGF excretion. A logistic regression analysis showed that the most significant independent risk factors for the deterioration of renal function with time are initial high (>11.8 pg/mgCr) UIL-6 excretion, initial low (<15.5 ng/mgCr) urinary UEGF excretion and male gender. In patients with newly diagnosed CGN, UIL-6 and UEGF can serve as prognostic biomarkers for the progression of the disease.